Search

Displaying results 3731 - 3740 of 6835 in total
  1. Drug

    Triclocarban

    go.drugbank.com/drugs/DB11155
    Approved

    In 2017, the US FDA prohibited the marketing of over-the-counter (OTC) consumer antiseptic wash products containing triclocarban due to negative health effects such as bacterial resistance or hormonal

  2. Drug

    CHO Cells Recombinant Vaccine

    go.drugbank.com/drugs/DB15893
    Experimental

    The vaccine candidate is sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. and is undergoing phase I clinical trials to evaluate safety and tolerability. … This vaccine candidate, developed in China, uses SARS-CoV-2 protein subunits that are entirely engineered, created, and secreted by Chinese Hamster Ovary (CHO) cells[A219758].

  3. Drug

    Berdazimer

    go.drugbank.com/drugs/DB18712
    Approved

    It releases NO through exposure to proton donors like water, which will degrade the N-diazeniumdiolate entity. … [A262965] On Jan 05, 2024, the FDA approved berdazimer under the brand name ZELSUVMI for the treatment of adult and pediatric molluscum contagiosum, and it is the first drug to be approved for this

  4. Drug

    Perflubutane

    go.drugbank.com/drugs/DB12821
    ApprovedInvestigationalWithdrawn

    It is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing; currently the leading procedure for detecting coronary heart disease.

  5. Drug

    Nitisinone

    go.drugbank.com/drugs/DB00348
    Approved

    Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria. It is sold under the brand names Orfadin and Harliku.

  6. Drug

    AC3056

    go.drugbank.com/drugs/DB05230
    Experimental

    It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials. … AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals.

  7. Drug

    Nalorphine

    go.drugbank.com/drugs/DB11490
    ExperimentalVet approved

    It is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to determine opioid dependence. … It acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics.

  8. Drug

    BMS-564929

    go.drugbank.com/drugs/DB07286
    Experimental

    So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause. … BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM).

  9. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

  10. Drug

    Ethiodized oil

    go.drugbank.com/drugs/DB00965
    ApprovedInvestigational

    Ethiodized oil is used by injection as a radio-opaque contrast agent. The composition of the oil is comprised of iodine combined with ethyl esters of fatty acids of poppyseed oil.